Restricted accessLetterFirst published online 2021-08
Incongruent Changes in Lab HbA1c and Average Glucose Underscore Significant Differences in Calibration Between Continuous Glucose Monitoring Systems During the Conduct of a Study on Glycemic Control in Type 1 Diabetes—Comment on Préau et al.
PréauY, ArmandM, GalieS, et al.: Impact of switching from intermittently scanned to real-time continuous glucose monitoring systems in a type 1 diabetes patient French cohort: an observational study of clinical practices. Diabetes Technol Ther, 2021:259–267.
2.
FreeStyle Libre 14 day user manual (US) DOC39764 Rev. B 07/18. https://www.accessdata.fda.gov/cdrh_docs/pdf16/P160030S017C.pdf. (accessed March18, 2021).
3.
Dexcom G4 Platinum: Summary of Safety and Effectiveness Data https://www.accessdata.fda.gov/cdrh_docs/pdf12/P120005S018b.pdf (accessed March28, 2021).
4.
DunnTC, XuY, HayterG, et al.: Real-world flash glucose monitoring patterns and associations between self-monitoring frequency and glycaemic measures: a European analysis of over 60 million glucose tests. Diabetes Res Clin Pract, 2018; 137:37–46.
5.
BergenstalRM, BeckRW, CloseKL, et al.: Glucose management indicator (GMI): a new term for estimating A1C from continuous glucose monitoring. Diabetes Care, 2018; 41:dc181581.
6.
BeckRW, BergenstalRM, ChengP, et al.: The relationships between time in range, hyperglycemia metrics, and HbA1c. J Diabetes Sci Technol, 2019; 13(4):614–626.
7.
SeiboldAS: Regarding: switching from flash glucose monitoring to continuous glucose monitoring on hypoglycemia in adults with type 1 diabetes at high hypoglycemia risk: the extension phase of the I HART CGM study-concerns that reduce confidence in conclusions regarding hypoglycemia. Diabetes Technol Ther, 2019; 21:97–98.
8.
ReddyM, OliverN: Reply to Letter by Seibold regarding Monika Reddy, Narvada Jugnee, Sinthuka Anantharaja, and Nick Oliver, Switching from Flash Glucose Monitoring to Continuous Glucose Monitoring on Hypoglycemia in Adults with Type 1 Diabetes at High Hypoglycemia Risk: the Extension Phase of the I HART CGM Study. Diabetes Technol Ther, 2019; 21:99–100.
